AVTX Stock Overview
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Avalo Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.98 |
| 52 Week High | US$1,130.39 |
| 52 Week Low | US$3.95 |
| Beta | 1.17 |
| 1 Month Change | 223.95% |
| 3 Month Change | 236.63% |
| 1 Year Change | -97.79% |
| 3 Year Change | -99.81% |
| 5 Year Change | -99.90% |
| Change since IPO | -99.87% |
Recent News & Updates
Recent updates
Avalo to get ~15M upfront in license deal with Apollo Therapeutics for AVTX-007
Aug 01Avalo Therapeutics announces one-for-twelve reverse stock split
Jul 06Is Cerecor (NASDAQ:CERC) A Risky Investment?
Aug 10
Cerecor enters into $35M debt financing agreement with Horizon Technology Finance
Jun 07What Kind Of Investors Own Most Of Cerecor Inc. (NASDAQ:CERC)?
Mar 10Have Insiders Been Buying Cerecor Inc. (NASDAQ:CERC) Shares?
Jan 18Armistice Capital adds 2.5M Cerecor shares for $6.5M
Jan 13Cerecor slumps 12% on stock and pre-funded warrants offering
Jan 07Cerecor gains on CERC-002 data in mid-stage COVID-19 study
Jan 05Cerecor trades higher as FDA accepts IND application for CERC-007
Dec 22Dosing underway in Cerecor's early-stage CERC-007 study in multiple myeloma
Dec 16Shareholder Returns
| AVTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 24.7% | 0.4% | 1.0% |
| 1Y | -97.8% | 0.9% | 21.9% |
Return vs Industry: AVTX underperformed the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: AVTX underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| AVTX volatility | |
|---|---|
| AVTX Average Weekly Movement | 101.9% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AVTX's share price has been volatile over the past 3 months.
Volatility Over Time: AVTX's weekly volatility has increased from 58% to 102% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 19 | Garry Neil | www.avalotx.com |
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company’s drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases.
Avalo Therapeutics, Inc. Fundamentals Summary
| AVTX fundamental statistics | |
|---|---|
| Market cap | US$15.49m |
| Earnings (TTM) | -US$31.54m |
| Revenue (TTM) | US$1.92m |
8.1x
P/S Ratio-0.5x
P/E RatioIs AVTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AVTX income statement (TTM) | |
|---|---|
| Revenue | US$1.92m |
| Cost of Revenue | US$9.95m |
| Gross Profit | -US$8.02m |
| Other Expenses | US$23.52m |
| Earnings | -US$31.54m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -30.50 |
| Gross Margin | -417.05% |
| Net Profit Margin | -1,639.50% |
| Debt/Equity Ratio | 0% |
How did AVTX perform over the long term?
See historical performance and comparison